NCT06678659RecruitingPhase 1/2
A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
A Phase 1 / 2, Open-Label Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
Source: ClinicalTrials.gov · Last updated 20 Aug 2026
Brief summary (registry, in English)
This is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of REC-1245 administered orally on a once daily (QD) schedule in participants with unresectable, locally advanced, or metastatic solid tumors.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 170 (estimated)
- First submitted
- 29 Oct 2024
- Start date
- 21 Nov 2024
- Primary completion date
- 30 Oct 2028
- Lead sponsor
- Recursion Pharmaceuticals Inc.
- Diseases
- Childhood cancers
- NCT number
- NCT06678659
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 170
- From 21 Nov 2024 to the primary completion date, 30 Oct 2028
- 7 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Received treatment with another RBM39 degrader
Other
- Clinically significant gastrointestinal (GI) or GI malabsorption
Who the study is looking for
- Have histologically-confirmed unresectable, locally advanced, or metastatic select solid tumors or select relapsed / refractory lymphoma
- Have experienced progressive disease, relapsed disease, or be intolerant to at least one established standard systemic anti-cancer treatment for a given tumor type, or have been considered ineligible for standard therapy.
- Eastern cooperative oncology group (ECOG) performance status ≤1; for adolescent participants, Lansky Performance Status Scale or Karnofsky Performance Status Scale score of ≥70.
- Measurable disease at baseline per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 / Lugano criteria and documented by computed tomography (CT) and / or magnetic resonance imaging (MRI)
Age in the registry: 12 years to - · Sex: All · Does not accept healthy volunteers
Sites (7)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| McGill University Health Centre (MUHC) - The Montreal Coordinator of this site? Confirm its status | Québec | Canada | Recruiting |
| Princess Margaret Cancer Centre Coordinator of this site? Confirm its status | Toronto | Canada | Recruiting |
| Cleveland Clinic Coordinator of this site? Confirm its status | Cleveland | United States | Recruiting |
| City of Hope Coordinator of this site? Confirm its status | Duarte | United States | Recruiting |
| SCRI Oncology Partners - PPDS Coordinator of this site? Confirm its status | Nashville | United States | Withdrawn |
| Sarcoma Oncology Research Center Coordinator of this site? Confirm its status | Santa Monica | United States | Recruiting |
| START Mountain Region Coordinator of this site? Confirm its status | West Valley City | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.